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Introduction
The progress in medicine, including the prolonged 
life expectancy, suggests that the number of older 
elderly patients with esophageal cancer will signifi-
cantly increase in the coming years. This group of pa-
tients is very heterogeneous with regard to co-mor-
bidity and physical reserve, while no clear guidelines 
of esophageal cancer management for the elderly 
are available. Regardless of the advance in surgical 
methods and chemoradiotherapy, the prognosis in 
this type of cancer remains poor. Despite the high 
incidence of this type of cancer among the elderly, 
no review relevant to geriatric patients is available.
Aim
The current study aimed to review the literature 
about the outcome of esophageal cancer in patients 
over 65.
Material and methods
A  systematic review of the literature was con-
ducted using the PubMed/Medline and Research-
Gate databases and by screening reference lists of 
articles. The databases were searched using the 
phrase “esophageal cancer” AND “elderly”. The titles, 
abstracts and full-text versions of studies published 
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between January 1, 2006 and November 11, 2016 
were sought out for inclusion in the review. Studies 
of populations aged over 65, treated for esophageal 
cancer, containing data about outcomes of the treat-
ment (e.g. morbidity, mortality, survival rates), writ-
ten in English, were included. Case reports, review 
papers and abstracts were excluded from the review. 
Finally 19 articles were chosen (Figure 1). Consid-
ering 13 studies, authors compared treatment out-
come between specified groups of patients. Cum-
mings et al. compared endoscopic treatment (ET) 
and open esophagectomy (OE) groups [1]. Li et al. 
compared OE and minimal invasive esophagecto-
my (MIE) groups [2]. Abrams et al. Tougeron et al. 
and compared OE and chemoradiotherapy (CRT) 
groups [3, 4]. Tougeron et al. presented the results 
in curative treatment, palliative treatment and best 
supportive care groups [5]. Tapias et al. analyzed 
3 groups based on age. Two of them concerned pa-
tients aged over 65 years (≥ 70 and ≥ 80) [6]. Among 
7 studies, two groups based on age were compared 
(younger vs. elderly) [6–12]. Only the groups consist-
ing of patients ≥ 65 years were analyzed.
Results
Tables I  and II include detailed information on 
population characteristics. Table III presents data on 
patients’ outcomes. All 19 articles were retrospec-
tive studies. In total, 6729 patients were included. 
Most of them were male (4888; 72.64%) while only 
23.36% (1841 patients) were female. The authors 
used four different scales to assess pre-treatment 
performance status of patients. Seven of them used 
the American Society of Anesthesiologists (ASA) 
score, five used the Charlson Comorbidity Index and 
one used the Eastern Cooperative Oncology Group 
(ECOG) score. The percentage of patients with co-
morbidities was in the range 29–84%. One thousand 
six hundred and thirty-six (51.45%) patients suf-
fered from adenocarcinoma and 1 439 (45.3%) from 
squamous cell carcinoma. The other cell types were 
rare (n = 105; 3.3%). Four hundred and eighty-two 
(47.6%) patients had a  tumor located in the lower 
third of the esophagus, 394 (38.9%) in the middle 
third and 137 (13.5%) in the upper third. Considering 
all studies which present data about cancer stage, 
167 (5.5%), 1565 (51.6%), 760 (25.1%), 445 (14.7%) 
and 95 (3.1%) patients were diagnosed with tumor 
stage 0, I, II, III and IV, respectively. Open esophagec-
tomy was the most common treatment method (n 
= 2.023; 30.1%). Five hundred and sixty-nine (8.5%) 
patients received chemoradiotherapy, 268 (4%) en-
doscopic treatment and 65 (1%) minimally invasive 
esophagectomy. Thirty (0.5%) patients received palli-
ative treatment consisting of photodynamic therapy 
(n = 1; 3.3%) or chemotherapy (n = 20; 66.7%). 666 
(9.9%) patients received best supportive care instead 
of curative treatment. According to the analyzed 
publications, 30-day mortality ranges from 3.2% to 
8.1%. Overall 5-year survival rates range from 0 to 
49.2%, and the median survival rate ranges from 
9.6 to 108.2 months. Twelve to seventy percent of 
patients who had undergone different types of ther-
apy suffered from treatment-related complications. 
Considering CRT, grade ≥ 3 toxicity was observed in 
22–36% of patients. The incidence of complications 
in the surgery group ranges from 27% to 69%. Med-
ical complications occurred more often than surgi-
cal ones. The most common were cardiopulmonary 
ones, such as pneumonia and arrhythmia. The most 
Literature search:
Databases: PubMed and ResearchGate
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   English-language articles only
   Full text only
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Figure 1. Flow diagram
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Table I. List of publications concerning esophageal cancer outcomes in the elderly and the most important 
data about the methodology of the publications
Authors Study 
period 
[years]
Number of 
patients 
(male/female)
Age 
[years]
Median age 
[years]
Type of 
treatment,  
n (%)
Follow-up period
Cummings et al.  
(OE group)
1994–2011 893 (691/202) > 66 74.3 ±5.4 OE 2 years
Liu, Huang et al.  
(≥ 70 y group)
2001–2012 39 (31/8) ≥ 70 75.1 ±3.6 OE Until death/until 
the end of research
Li et al. (OE group) 2005– 2013 58 (44/14) > 70 72 (70–85) OE Until death/until 
the end of research
Aydin et al. 1998–2010 37 (13/24) ≥ 70 74 ±3.7 (70–83) OE Until death/until 
the end of research
Pultrum et al.  
(≥ 70 y group)
1991–2007 64 (52/12) ≥ 70 74.5 OE Until death/until 
the end of research
Liu, Chen et al.  
(≥ 70 y group)
1999–2007 29 (22/7) > 70 75.2 ±3.6 OE Until death/until 
the end of research
Kosugi et al. (OE group) 1992–2003 40 (38/2) ≥ 70 77 (75–85) OE Until death/until 
the end of research
Abrams et al. (OE group) 1991–2002 341 (257/84) ≥ 65 nd OE Until death/until 
the end of research
Internullo et al. 1991–2006 108 (76/32) ≥ 76 nd OE Until death/until 
the end of research
Ruol et al. (≥ 70 y group) 1992–2005 159 (124/35) ≥ 70 73.1 (71.6–76.6) OE Until death/until 
the end of research
Ma et al. (≥ 70 y group) 1990–2004 60 (51/9) ≥ 70 73.1 ±3.9 OE 6 months
Mirza et al. (≥ 70 y group) 1996–2010 46 (37/9) ≥ 70 nd OE Until death/until 
the end of research
Li et al. (MIE group) 2005– 2013 58 (44/14) > 70 72 (70–79) MIE Until death/until 
the end of research
Cummings et al.  
(ET group)
1994–2011 255 (197/58) > 66 77.5 ±6.4 ET 2 years
Kikuchi et al.  
(≥ 75 y group)
2005–2011 13 (11/2) ≥ 70 79 (76–87) ESD 7 days
Wakui et al. 2003–2008 22 (19/3) ≥ 75 79 (75–85) CRT Until death/until 
the end of research
Kosugi et al. (CRT group) 1992–2003 24 (21/3) ≥ 70 77 (75–85) CRT Until death/until 
the end of research
Abrams et al. (CRT group) 1991–2002 389 (261/128) ≥ 65 nd CRT 10 years
Tougeron, Di Fiore et al. 1994–2007 109 (90/19) ≥ 70 74.4 ±3.7 (70–88) CRT Until death/until 
the end of research
Anderson et al. 1996–2001 25 (14/11) 65–70  
(n = 2) 
≥ 70  
(n = 23)
77 (66–88) CRT Until death/until 
the end of research
Urszula A. Skorus, Jakub Kenig
Videosurgery and Other Miniinvasive Techniques 4, December/2017344
Table I. Cont.
Authors Study 
period 
[years]
Number of 
patients 
(male/female)
Age 
[years]
Median age 
[years]
Type of 
treatment,  
n (%)
Follow-up period
Tougeron et al.  
(curative treatment)
1994–2007 151 (124/27) ≥ 70 74.9 ±4.1 Mucosectomy: 
6 (4.0)
PDT: 14 (9.3)
Surgery: 13 (8.6)
CRT: 111 (73.5)
RT: 7 (4.6)
Until death/until 
the end of research
Tougeron et al. (palliative 
treatment group)
1994–2007 30 (27/3) ≥ 70 74.2 ±4.0 PDT: 1 (3.3)
CT: 20 (66.7)
Until death/until 
the end of research
Tougeron et al.  
(BSC group)
1994–2007 101 (65/36) ≥ 70 80.0 ±6.6*
78.2 ±5.8**
PDT: 3 (4.3)*
CT: 2 (2.9)*
Until death/until 
the end of research
Tapias et al.  
(70–79 y group)
2002–2011 124 (99/25) 70–79 73.8 ±2.9 MIE (n = 7)
OE (n = 133)
10 years
Tapias et al. (≥ 80 y group) 2002–2011 16 (10/6) ≥ 80 82.2 ±1.6 MIE (n = 0)
OE (n = 16)
10 years
Steyerberg et al. 1991–1999 3538 
(2470/1068)
≥ 65 nd Combinations 
of OE, CT and  
RT (n = 2973)
BSC (n = 565)
Until death/until 
the end of research
ET – endoscopic treatment (ablation/endoscopic mucosal resection), OE – open esophagectomy, EMR – endoscopic mucosal resection, MIE – minimal invasive 
esophagectomy, ESD – endoscopic submucosal dissection, CRT – chemoradiotherapy, PDT – photodynamic therapy, RT – radiotherapy, CT – chemotherapy, 
BSC – best supportive care, *patients without visceral metastasis/metastases, **patients with visceral metastasis/metastases, nd – no data.
important surgical complications were anastomotic 
leakage, wound infection and chylothorax.
Discussion
Histology type, location and stage
All publications included detailed information 
about the cancer histology type. Most of them pro-
vide information about tumor location and stage. 
Three studies described connection between cancer 
histology type and outcome. Cummings et al. noted 
that patients with adenocarcinoma (AC) who un-
derwent open esophagectomy (OE) or endoscopic 
treatment (ET) had poorer 2-year survival compared 
to squamous cell carcinoma (SCC) patients (60% vs. 
76%; p < 0.01) [1]. However, Abrams et al. reported 
that SCC patients were refused surgery more often, 
but AC patients treated with chemoradiotherapy 
(CRT) had worse overall and disease-specific sur-
vival than the SCC group. They noted that there is 
a difference in response to CRT between AC and SCC. 
Considering their results, older patients with AC can 
benefit from CRT more than SCC patients, but the 
protocol of chemoradiotherapy is not reported in the 
study. It is believed that this study may be underpow-
ered to reveal such an advantage of CRT for SCC pa-
tients [3]. Anderson et al. found no significant differ-
ence in 2-year survival between AC and SCC groups 
treated with CRT consisting of 5-FU, mitomycin and 
radiation, but this can be explained by the small co-
hort size (25 patients) [13]. Comparing these results, 
it is difficult to determine which cancer type has 
a better prognosis among the elderly, because the 
conclusions of the studies are conflicting. More ad-
vanced tumor stage is a well-known factor of worse 
prognosis. It has also been confirmed by two stud-
ies, which revealed poorer overall survival among 
elderly patients with a more advanced cancer stage 
(I/II stage HR = 0.052; 95% CI: 0.005–0.039) [15], 
(HR = 1.63; 95% CI: 1.32–2.00) [7]. Another study 
showed that CRT patients diagnosed with stage I 
had higher disease-specific mortality than the group 
with stage II tumors. Surprising though it may be, 
in this study patients with more advanced disease 
were more likely to receive esophagectomy as a first-
line therapy [3]. Two authors found no difference in 
overall survival considering groups based on tumor 
stage [4, 8]. However, this was not elaborated on in 
the discussion. Aydin et al. found that histology type, 
tumor location and tumor stage were not prognos-
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Table II. List of publications concerning esophageal cancer outcomes in the elderly and the most important 
data about the population
Authors Histology, n (%) Tumor stage, n (%) Tumor site
SCC AC Other 0 I II III IV L1/3 M1/3 U1/3
Cummings et al. 
(OE group)
261 
(29.23)
632 
(70.77)
0 (0) 88 (9.9) 805 (90.1) 0 (0) 0 (0) 0 (0) nd nd nd
Liu, Huang et al. 
(≥ 70 y group)
30 (76.9) 9 (23.1) 0 (0) 0 (0) 0 (0) 20 (51.3) 14 (35.9) 5 (12.8) 17 (43.6) 16 (41.0) 6 (15.4)
Li et al.  
(OE group)
58 (100) 0 (0) 0 (0) 0 (0) 3 (5.2) 30 (51.7) 25 (43.1) 0 (0) 6 (10.3) 42 (72.4) 10 (17.2)
Aydin et al. 27 (73.0) 6 (16.2) 4 (10.8) 0 (0) 4 (10.8) 19 (51.4) 14 (37.8) 0 (0) 18 (48.6) 17 (46.0) 2 (5.4)
Pultrum et al. 
(≥ 70 y group)
8 (13) 56 (87) 0 (0) 0 (0) 11 (17) 25 (52) 25 (39) 3 (5) 60 (94) 4 (6) 0 (0)
Liu, Chen et al. 
(≥ 70 y group)
26 (89.7) 3 (10.3) 0 (0) 0 (0) 0 (0) 14 (48.2) 11 (37.9) 4 (13.8) 13 (44.8) 11 (37.9) 5 (17.2)
Kosugi et al. 
(OE group)
40 (100) 0 (0) 0 (0) 0 (0) 11 (27.5) 15 (37.5) 11 (27.5) 3 (7.5) 18 (45.0) 19 (47.5) 3 (7.5)
Abrams et al. 
(OE group)
94 (27.5) 213 (62.5) 34 (10.0) 0 (0) 177 (51.9) 164 (48.1) 0 (0) 0 (0) nd nd nd
Internullo et al. 26 (24) 80 (74) 2 (1.8) 6 (5.5) 29 (26.8) 25 (23.1) 29 (26.7) 19 (17.5) 93 (86.1) 13 (12) 2 (1.8)
Ruol et al. 
(≥ 70 y group)
77 (48.4) 77 (48.4) 5 (3.2) 5 (3.2) 20 (12.7) 71 (44.2) 50 (31.9) 11 (7.0) 94 (59.1) 37 (23.3) 28 (17.6)
Ma et al. 
(≥ 70 y group) 
53 (88.3) 4 (6.7) 3 (5.0) 1 (1.7) 2 (2.2) 9 (15.0) 45 (75.0) 3 (5.0) 16 (26.7) 32 (53.3) 10 (16.7)
Mirza et al. 
(≥ 70 y group)
45 (97.83) 1 (2.17) 0 (0) nd nd nd nd nd nd nd nd
Li et al. 
(MIE group)
58 (100) 0 (0) 0 (0) 0 (0) 4 (6.9) 31 (53.4) 23 (39.7) 0 (0) 8 (13.8) 44 (75.9) 6 (10.3)
Cummings et al. 
(ET group)
78 (31) 177 (69) 0 60 (23.5) 195 (76.5) 0 (0) 0 (0) 0 (0) nd nd nd
Kikuchi et al. 
(≥ 75 y group)
13 (100) 0 (0) 0 (0) nd nd nd nd nd 1 (8) 9 (69) 3 (23)
Wakui et al. 22 (100) nd nd 0 (0) 3 (13.64) 6 (27.27) 12 (54.55) 1 (4.55) nd 10 (46) nd
Kosugi et al. 
(CRT group)
24 (100) 0 (0) 0 (0) 0 (0) 1 (4.2) 14 (58.3) 7 (29.2) 2 (8.4) 3 (12.5) 15 (62.5) 6 (25.0)
Abrams et al. 
(CRT group)
209 (53.7) 141 (36.3) 39 (10.0) 0 (0) 232 (59.6) 157 (40.4) 0 (0) 0 (0) nd nd nd
Tougeron,  
Di Fiore et al.
77 (70.6) 28 (25.7) 4 (3.7) 0 (0) 2 (1.8) 50 (45.9) 46 (42.2) 6 (5.5) 52 (47.7) 36 (33.3) 21 (19.3)
Anderson et al. 13 (52) 12 (48) 0 (0) 0 (0) 0 (0) 8 (32) 17 (68) 0 (0) nd nd nd
Tougeron et al. 
(curative treat-
ment)
103 (70.1) 44 (29.9) 0 (0) 0 (0) 24 (15.9) 61 (40.4) 51 (33.8) 7 (4.6) 80 (60.0) 44 (29.1) 27 (17.9)
Tougeron et al. 
(palliative treat-
ment group)
17 (56.7) 12 (40.0) 1 (3.3) 0 (0) 0 (0) 0 (0) 0 (0) 30 (100) 19 (63.3) 9 (30.0) 2 (6.7)
Tougeron et al. 
(BSC group)
63 (67.02)27 (28.72) 4 (4.26) 0 (0) 3 (4.3) 7 (10.1) 18 (26.1) 1 (1.4) 52 (51.49)33 (32.67) 16 (15.84)
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Table II. Cont.
Authors Histology, n (%) Tumor stage, n (%) Tumor site
SCC AC Other 0 I II III IV L1/3 M1/3 U1/3
Tapias et al. 
(70–79 y group)
15 (12.1) 100 (80.7) 9 (7.2) 7 (6.2) 34 (30.1) 29 (25.7) 43 (38.1) 0 (0) nd nd nd
Tapias et al. 
(≥ 80 y group)
2 (12.5) 14 (87.5) 0 (0) 0 (0) 5 (35.7) 5 (35.7) 4 (28.6) 0 (0) nd nd nd
Steyerberg et al. nd nd nd nd nd nd nd nd nd nd nd
L1/3 – lower third, M1/3 – middle third, U1/3 – upper third, SCC – squamous cell carcinoma, AC – adenocarcinoma, nd – no data.
tic factors for treatment-related complications and 
mortality, but only 37 patients were included in their 
study [14].
Comorbidities
Performance status was assessed to evaluate 
individual risk of therapy, and to decide the treat-
ment approach. Ruol et al. noted that, compared to 
the younger population, the elderly were excluded 
from surgery more often because of comorbidities 
(40% vs. 20%) [9]. Two papers mentioned “de-
creased functional body reserves” as a reason why 
elderly patients were considered unfit for surgery, 
but no detailed definition of decreased body reserve 
and assessment of frailty syndrome was reported 
[7, 15]. Three studies noted a  significant impact 
of comorbidities on long-term survival [4, 7, 16]. 
Liu et al. identified poorer pulmonary function and 
limited functional reserve as a  risk factor for high-
er mortality and morbidity after OE [7]. Among the 
articles, the usefulness of performance status scores 
was discussed. Tougeron et al. have shown that the 
Charlson score can be used as a  prognostic factor 
for median overall survival (13.9 ±3.6 months Charl-
son score ≤ 2 vs. 4.1 ±2.6 months Charlson score 
> 2; HR = 2.1, 95% CI: 1.0–4.5; p = 0.046). Patients 
with a score ≥ 1 who underwent chemoradiothera-
py were more likely to experience grade 2 or more 
toxicity (76.5% vs. 51.2%, p = 0.02) and chemother-
apy delay (66.7% vs. 39.5%, p = 0.01) [4]. Steyer-
berg et al. described poorer survival in patients with 
a  Charlson score ≥ 2 [16]. Pultrum et al. used the 
ASA score to assess patients, and did not consider it 
as a prognostic factor, but found that cardiovascular 
comorbidity among the elderly was a risk factor for 
postoperative comorbidity [8]. Tougeron et al. found 
no prognostic value of the Charlson score [5].
Effect of age
Eight studies, concerning surgical treatment, 
compared populations based on age. There was no 
study on chemoradiotherapy (CRT) comparing such 
groups. Only three papers have shown a significant 
difference in outcomes. Median survival described in 
one study differed in elderly and younger patients 
(151–306 days vs. 350–944 days) [16]. Moreover, 
there was a significant difference in the overall com-
plication rate (53.6% (< 70 years) vs. 62.1% (70–79 
years) vs. 87.5 (≥ 80 years); p = 0.011) [6]. Another 
study showed a significant increase in cardiac and 
pulmonary complications in patients aged ≥ 70 (pul-
monary: 43.3% vs. 28.1%: p = 0.01; cardiac: 28.3% 
vs. 19.8%, p = 0.001), but no difference in the over-
all complication rate [10]. Age ≥ 70 was associated 
with longer intensive care unit stay with a median 
of 7 days (range: 1–64) in elderly versus young-
er patients, with a median of 3 days (range: 1–56) 
(95% CI: –9.95 to –1.86; p = 0.005) [8]. The report of 
Tapias et al. was the only study to show that elderly 
patients treated with less intensive radiotherapy or 
chemoradiotherapy had longer overall survival than 
younger patients (15.8 months vs. 13.7 months). The 
authors suggest that it can support the thesis that 
the tumor growth and metastatic spread become 
slower with aging. Considering the advantages of 
advanced age, another study showed decreased in-
cidence of anastomotic stricture in the elderly group 
(OR = 0.99; p = 0.574). The authors postulated that 
the attenuated inflammatory response in the elder-
ly leads to less collagen deposition and fibrosis [6]. 
Liu et al. observed longer survival time in the elderly 
treated with less intensive chemotherapy following 
esophagectomy in comparison to younger ones, but 
the results were statistically insignificant (median 
survival time 15.8 m vs. 13.7 m; p = 0.44). The other 
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Table III. List of publications concerning esophageal cancer outcomes in the elderly and the most important 
data about the outcomes
Authors Pre-treatment 
comorbidity 
assessment 
score
Mortality, 
n (%)
All  
complications/ 
toxicity, n (%)
Overall survival rates (%) Median  
overall  
survival 
[months]
Recurrent 
disease,  
n (%)
1 year 2 years 3 years 5 years
Cummings 
et al.  
(OE group)
Charlson/
Deyo comor-
bidity index
36 (4)2 265 (30) nd 71 (AC)
60 (SCC)
nd nd nd 139 (16)
Liu, Huang 
et al. 
(≥ 70 y group)
nd 3 (7.7)5 18 (46.1) nd 33.3 0 nd 15.8 nd
Li et al.  
(OE group)
nd 5 (8.6)5 35 (60.3) nd nd nd nd 22 ±3.4 nd
Aydin et al. nd 3 (8.1)1 16 (43.2) 70.3 nd 31 21.4 28.7 6 (16.2)
Pultrum  
et al.  
(≥ 70 y group)
ASA 7 (11)3 44 (69) 70 nd nd 33 26 (range: 
0–199)
27 (42)
Liu Chen  
et al.  
(≥ 70 y group)
ECOG 3 (10.3)4 15 (51.7) nd 20 3 0 12.1 (95% CI: 
8.6–15.6)
nd
Kosugi et al. 
(OE group)
ASA 2 (5)1 26 (65.0) 77.5 nd 37.3 24.0 108.2 (range: 
32.5–138.9)
nd
Abrams et al. 
(OE group)
Charlson/
Klabunde 
comorbidity 
index
24 (7.7)1 nd nd nd 53.1 44.9 nd nd
Internullo 
et al.
ASA 8 (7.4)5 56 (51.9) nd nd nd 35.7 28.5 (range: 
0.1–149.5)
(33.3)
Ruol et al.  
(≥ 70 y group)
ASA 3 (1.9)1
3 (1.9)4
78 (49.1) nd nd nd 35.4 17.9 (range: 
9.2–44.4)
nd
Ma et al.  
(≥ 70 y group)
nd 2 (3.3)4 nd nd nd nd nd nd nd
Mirza et al.  
(≥ 70 y group)
ASA nd nd nd nd nd nd 10.8 (range:  
< 1 month to 
8.3 years)
21 (45.65)
Li et al.  
(MIE group)
nd 2 (3.4)5 22 (37.9) nd nd nd nd 39 ±8.9 nd
Cummings  
et al.  
(ET group)
Charlson/
Deyo comor-
bidity index
nd 30 (12) nd 84 (AC) 
76 (SCC)
nd nd nd 32 (13)
Kikuchi et al. 
(≥ 75 y group)
ASA 0 (0)5 13 (27) nd nd nd nd nd nd
Wakui et al. nd 4 (18.2)5 14 (70) 44.3 
±10.8
34.5 
±10.4
15.9 
±10.8
nd 23.8 (range: 
8.3–53.6)
11 (55)
Kosugi et al. 
(CRT group)
ASA 5 (21)6 nd 60.9 nd 17.4 11.6 72.5m (range: 
12.4–95.3)
1 (4.1)
Abrams et al. 
(CRT group)
Charlson/
Klabunde 
comorbidity 
index
nd nd nd nd 23.9 13.9 nd nd
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Authors Pre-treatment 
comorbidity 
assessment 
score
Mortality, 
n (%)
All  
complications/ 
toxicity, n (%)
Overall survival rates (%) Median  
overall  
survival 
[months]
Recurrent 
disease,  
n (%)
1 year 2 years 3 years 5 years
Tougeron,  
Di Fiore et al.
Charlson score 2 (2.2)5 62 (56.9) 56.9 19.27 6.4 15.2 ±2.8 31 (28.4)
Anderson 
et al.
Charlson score 0 (0)5 9 (36) 80 64 nd nd 35 (3–66) nd
Tougeron  
et al. (curative 
treatment)
Charlson score nd nd nd nd nd nd 17.8 ±1.5*
5.5 ±2.0**
35 (23.17)
Tougeron et 
al. (palliative 
treatment 
group)
Charlson score nd nd nd nd nd nd 6.7 ±2.1 7 (23.33)
Tougeron 
et al.  
(BSC group)
Charlson score nd nd nd nd nd nd 5.5 ±2.0*
1.8 ±0.4**
18 (17.82)
Tapias et al.  
(70–79 y 
group)
nd 4 (3.2)1
7 (6.1)3
77 (62.1) nd nd nd 41.7 nd nd
Tapias et al.  
(≥ 80 y group)
nd 1 (6.3)1
2 (14.3)3
14 (87.5) nd nd nd 49.2 nd nd
Steyerberg 
et al.
Charlson score nd nd 42 24 nd 11 9.63 (95% CI: 
9.2–10)
nd
130-day mortality, 260-day mortality, 390-day mortality, 4in-hospital mortality, 5no data, 6treatment-related mortality, *patients without visceral metastasis/
metastases, **patients with visceral metastasis/metastases, nd – no data.
Table III. Cont.
studies also found no significant difference in mor-
tality, morbidity or long-term survival in younger and 
older group [8, 9, 11, 17]. 
Methods of treatment
Due to the retrospective character of studies, 
little is known about the process of therapeutic 
decision making. Two studies have shown a  ten-
dency for less invasive procedures to be conduct-
ed in older than in younger patients. Older age 
was associated with more frequent use of ET in-
stead of OE [1]. Moreover, elderly patients were 
more likely to undergo transhiatal than transtho-
racic esophagectomy compared to the younger 
group [18]. Carcinoma in situ was considered as 
an indication for ET [1, 5]. One study considered 
advanced disease (≥ T3 and unresectable nodes) 
as a  reason for refusing surgery [18]. Although 
the management of esophageal cancer in the el-
derly population is still discussed, esophagecto-
my seems to be the mainstay of treatment for 
patients with esophageal cancer [12]. Regardless 
of development of surgical techniques, there are 
still high mortality and morbidity involved in this 
procedure [5, 12]. Accordingly, some less invasive 
methods of treatment such as minimal invasive 
esophagectomy (MIE) or endoscopic treatment 
are being trialed [1, 2, 11]. Chemoradiotherapy 
alone is also considered a  promising treatment 
method in some cases [5, 13, 16]. Cummings et al. 
observed decreased mortality (HR = 0.51; 95% CI: 
0.36–0.73) and 2-year survival (HR = 0.61; 95% CI: 
0.45–0.85) in the ET group (compared to OE), but 
only patients with early stage tumor (0, I) were op-
erated on in such a way. Li et al. reported a signifi-
cantly lower rate of overall complications in the 
MIE group than in the OE group (37.9 vs. 60.3, p = 
0.016). In this study patients with stages I and II 
were included. 
Kikuchi et al. observed no mortality in their 
study on endoscopic submucosal dissection, but it 
also pertains only to early stages of cancer (tumor 
diameter < 2 cm) and can be explained with non-in-
vasive character of the procedure [11]. 
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Quality of life
Unfortunately, no study has addressed the quality 
of life. Some complications such as esophageal stric-
ture, vocal cord palsy or a need for tracheostomy can 
provide some data on this matter, but they cannot 
substitute detailed psychological analysis [19, 20].
Conclusions
Chronological age seems to have little influence 
on outcome of esophageal cancer treatment [7, 9, 11, 
12, 14, 17]. Therefore, advanced age should not be 
considered as a contraindication for esophagectomy, 
but the risk should be evaluated individually. Current-
ly, no study takes into consideration detailed geriatric 
assessment identifying the frailty state of the patient. 
There is also no study showing outcomes reported by 
patients that would present to the physicians the old-
er patients’ view of the treatment process. Therefore, 
there is a  great need for well-designed prospective 
studies including full geriatric assessment.  
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